Biologic Agents and Secondary Immune Deficiency
Copyright © 2019 Elsevier Inc. All rights reserved..
Biologics are protein-based pharmaceuticals derived from living organisms or their proteins. We discuss the mechanism of action for currently approved biologics and a give summary of the studies on immune suppression from biologics. Most of these studies have been conducted with rheumatology patients, and many in adults. Their relevance for children is explored and existing gaps in data for children are highlighted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Pediatric clinics of North America - 66(2019), 5 vom: 03. Okt., Seite 1007-1020 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Axelrod, Heather [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-inflammatory |
|---|
| Anmerkungen: |
Date Completed 23.01.2020 Date Revised 23.01.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pcl.2019.06.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300760655 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300760655 | ||
| 003 | DE-627 | ||
| 005 | 20231225103224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pcl.2019.06.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM300760655 | ||
| 035 | |a (NLM)31466676 | ||
| 035 | |a (PII)S0031-3955(19)30091-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Axelrod, Heather |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologic Agents and Secondary Immune Deficiency |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2020 | ||
| 500 | |a Date Revised 23.01.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a Biologics are protein-based pharmaceuticals derived from living organisms or their proteins. We discuss the mechanism of action for currently approved biologics and a give summary of the studies on immune suppression from biologics. Most of these studies have been conducted with rheumatology patients, and many in adults. Their relevance for children is explored and existing gaps in data for children are highlighted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-inflammatory | |
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Secondary immune deficiency | |
| 650 | 4 | |a TNF-α inhibitors | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 700 | 1 | |a Adams, Matthew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric clinics of North America |d 1953 |g 66(2019), 5 vom: 03. Okt., Seite 1007-1020 |w (DE-627)NLM000121614 |x 1557-8240 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2019 |g number:5 |g day:03 |g month:10 |g pages:1007-1020 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pcl.2019.06.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2019 |e 5 |b 03 |c 10 |h 1007-1020 | ||